Pulmonary hypertension (PH)
There are five groups of PH, as defined by the World Health Organization (WHO). All are severe diseases characterised by high blood pressure in the lungs.[1]
Our focus has been on a specific, rare form of PH (WHO Group 1) called pulmonary arterial hypertension (PAH), but our research covers all groups of PH.[1]
We want to:
- Drive early identification and diagnosis of PH; developing educational and screening solutions to speed up referrals to specialist centres
- Maximise the clinical benefits of our current medicines
- Build an innovative drug development future that focuses on new ways to tackle PH
- Provide holistic support for those affected by PAH, to improve overall wellbeing and quality of life
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
Despite recent advances, PAH remains a severely debilitating condition that leads to heart disease and early death.[5], [8] Early diagnosis and treatment are critical to helping improve life expectancy,[10] but PAH is difficult to diagnose and there is currently no cure.[2]
At Johnson & Johnson, we are committed to transforming pulmonary arterial hypertension into a long-term, manageable condition so that patients can live a full life. Our integration has created unique perspectives, opportunities and capabilities that we hope will provide new possibilities for the PH community.”
We bring to the field of PH a remarkable track record in scientific discovery and a deep patient-centric focus, underpinned by an open, transparent business culture.
We are pleased to collaborate with patient organisations in supporting their mission to empower patients with PH to optimally manage their disease and lead as full a life as possible.
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
References
[1] Humbert M, , et al 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43(38):3618–3731.
[2] Pulmonary Hypertension Association. About PH. Available at https://phassociation.org/patients/aboutph/. accessed October 2022.
[3] Benza RL, et al. An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry. Chest 2012; 142:448 56.
[4] Hoeper MM, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50:1700740.
[5] Vachiéry JL, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev 2012; 21:313-20.
[6] Prins KW, et al. WHO Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. Cardiol Clin 2016; 34(3):363 74.
[7] Humbert M, et al. Pulmonary Arterial Hypertension in France. Am J Respir Crit Care Med 2006; 173:1023 30.
[8] Armstrong I, et al. The patient experience of pulmonary hypertension: a large cross sectional study of UK patients. BMC Pulm Med 2019; 19:67.
https://doi.org/10.1186/s12890-019-0827-5.
[9] Hoeper MG, Gibbs SR. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev 2014; 23:450-7.
[10] Brown LM, et al. Delay in recognition of pulmonary arterial hypertension. Factors identified from the REVEAL registry. Chest 2011; 140(1):19-26.
CP-459038
September 2024